Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.
about
Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Patients with Frailty, Medical Comorbidities or Prior Lower Urinary Tract SurgeryClinical use of the β3 adrenoceptor agonist mirabegron in patients with overactive bladder syndromeTotal urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptomsThe effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trialsCUA guideline on adult overactive bladderCost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada.Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies.Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE)Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence.Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.Postmenopausal overactive bladderThe efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial.New medical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and future perspectivesMirabegron: a Beta-3 agonist for overactive bladder.Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison.Overactive bladder - 18 years - Part IIImpact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency.Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life.Efficacy and Tolerability of Solifenacin 5 mg Fixed Dose in Korean Children with Newly Diagnosed Idiopathic Overactive Bladder: a Multicenter Prospective Study.Mirabegron: a review of its use in patients with overactive bladder syndrome.Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.Mirabegron in the treatment of overactive bladder.Cost-effectiveness of novel therapies for overactive bladder.Latest pharmacotherapy options for benign prostatic hyperplasia.Sacral neuromodulation: an effective treatment for lower urinary tract symptoms in multiple sclerosis.Persistence and adherence to overactive bladder medications in Japan: A large nationwide real-world analysis.OnabotulinumtoxinA Treatment for Overactive Bladder in the Elderly: Practical Points and Future Prospects.Urinary incontinence in men: current and developing therapy options.Clinical and economic impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada.Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.Treatment of Concomitant OAB and BPH.Overactive bladder in children.Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives.Persistence with mirabegron therapy for overactive bladder: A real life experience.Conjoint Urological Society of Australia and New Zealand (USANZ) and Urogynaecological Society of Australasia (UGSA) Guidelines on the management of adult non-neurogenic overactive bladder.Patient-reported outcomes with the β3 -adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder.Clinical Guideline for Female Lower Urinary Tract Symptoms.A clinical perspective on the analysis and presentation of the number of incontinence episodes following treatment for OAB.Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
P2860
Q26749608-D6000977-0919-49F6-8275-3426D55A033EQ26783536-952CEF6B-2524-4C88-98B1-9ED839DE464EQ27001248-15663753-A7A7-4B8E-99F8-6D195778FE83Q30894093-D199165A-605B-406B-80A4-1BF2BD067FD2Q33665026-55A331B5-3B2C-4E05-8C64-A5150E5707B8Q33696642-F88EE660-B216-46C8-8DB0-E5CE9E1C9274Q33727733-1A1B30D3-298F-460B-BCA6-4539D168E9A0Q33835874-FB176CA5-89B9-4EC3-A94A-47E6241B52B5Q34405906-005780E8-FF8C-47E7-B4A2-F78D910AB1EDQ34502903-5906F92C-B0E3-4297-B8F2-DAAC38779C84Q35157329-94AB372B-91F1-46F3-AEBE-A650F254874FQ36086072-CFD2215C-304A-4EB9-B6A9-BC769871E815Q36133212-9CB942CE-53F7-4DB9-9BBD-B903C696A1C8Q36160960-C3B980DA-D89B-4CAC-9B5A-AC4EA9E0BA04Q36625281-40BE4D53-B0B4-4FFC-A24A-601A00184123Q36912766-5BE5A5DB-CCF9-44B7-A481-A2415D8F842FQ37306067-ED6B7F96-F07F-4DF0-BDB5-6C0A1000DEF0Q37390990-E9BDDA21-6CD0-4397-A28A-8C3040656A58Q37570247-44F81614-9B9F-4701-9C05-ECB40734FD45Q38118658-D8C5EDC6-3CEE-4BE8-B5AC-430292A387F7Q38152756-1951EB8D-A695-456A-8A99-6A51CA4AB6C4Q38197276-D2965BE4-8AF5-4491-A0E9-9E019A73DBD6Q38210254-0A65143B-0379-45C7-A4C7-EC813AAABDEDQ38244053-B1595D8B-D24A-42DD-9F7B-71EB34F09870Q38544122-7BA3BAAE-F3A1-42B5-ACDE-EDC788967B5FQ38612038-2EF37F1A-07D6-4B72-BA27-CC6D141D37F3Q38669033-3BD024CB-973D-4535-B83D-0DD59897ECF8Q38708104-1657F08E-A157-4C4D-ABF1-68CA8D7C5DA7Q38911819-0755CFEB-D3D9-4304-A5AB-63983E7EE3F6Q39046374-73801B5F-B357-4BCB-A76A-34A5965E8484Q39090324-6AD234FA-C7EF-414C-A823-DDC3C48D0C84Q39164669-B188D4F2-C46C-4F51-9025-AF293B53B561Q39211584-2B91407E-AC04-4EAF-9BE1-4B54C23CCC3DQ39667385-CD6949CF-839A-4276-A704-F383FE0F6F37Q40210488-24157786-DA50-4955-910E-F45CC9DAF856Q40443607-B1934521-2ECC-41CC-BE60-443E1B9AAF84Q40627462-E7BCE7C2-9A26-4DC0-BABF-643DE0C0FDD1Q40963346-A8B8D9D2-C196-434A-9BE4-18F4935FA4C2Q40988066-ED9BF901-FA25-4414-8C2B-027CA30B3318Q43928336-08E4A8B2-DE5F-4631-A3BE-00316BE33A9B
P2860
Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mirabegron for the treatment o ...... controlled, phase III studies.
@en
Mirabegron for the treatment o ...... controlled, phase III studies.
@nl
type
label
Mirabegron for the treatment o ...... controlled, phase III studies.
@en
Mirabegron for the treatment o ...... controlled, phase III studies.
@nl
prefLabel
Mirabegron for the treatment o ...... controlled, phase III studies.
@en
Mirabegron for the treatment o ...... controlled, phase III studies.
@nl
P2093
P2860
P356
P1476
Mirabegron for the treatment o ...... -controlled, phase III studies
@en
P2093
C Dorrepaal
E Siddiqui
J Cambronero
M B Blauwet
N E Martin
P van Kerrebroeck
S Herschorn
P2860
P304
P356
10.1111/IJCP.12194
P577
2013-05-21T00:00:00Z